Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to pazopanib
GSK is a benzodiazepine class molecule. Any serious known immediate or delayed hypersensitivity reaction(s) to GSK or idiosyncrasy to drugs chemically related to the investigational drug.
Has a known immediate or delayed hypersensitivity reaction or idiosyncrasy to dasatinib
Patients with a known allergy or delayed hypersensitivity reaction to drugs chemically related to X- (e.g., crizotinib) or to the active ingredient of X-.
Patients with a known immediate or delayed hypersensitivity reaction or idiosyncrasy to talimogene laherparepvec or any of its components, capecitabine, fluorouracil (-FU) and / or oxaliplatin are ineligible
Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to IGF or methotrexate.
Have a known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to GSK or lysine-specific demethylase  (LSD) inhibitors that contraindicates their participation
Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to GSK, or any of the components of the study treatment.
Known immediate or delayed hypersensitivity reaction or idiosyncratic reaction to drugs chemically related to GSK, or any of the components of the study treatment.
Any serious known immediate or delayed hypersensitivity reaction to GSK or idiosyncrasy to drugs chemically related to the investigational drugs. Additionally, any known hypersensitivity to either enzalutamide, abiraterone or any excipients would be excluded.
Have a known immediate or delayed hypersensitivity reaction or idiosyncrasy to talimogene laherparepvec or any of its components or nivolumab, or history of severe hypersensitivity reaction to any monoclonal antibody
Have a known immediate or delayed hypersensitivity reaction or idiosyncrasy to talimogene laherparepvec (T-VEC) or any of its components
Have a known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to AT
Have a known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to everolimus that in the opinion of the investigator contraindicates their participation
Previous severe hypersensitivity reaction to another Monoclonal antibody. Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to the excipients in pazopanib tablets
GSK is a benzodiazepine class molecule. Any serious known immediate or delayed hypersensitivity reaction(s) to GSK or idiosyncrasy to drugs chemically related to the investigational drug.
Have a known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to GSK or LSD inhibitors that contraindicates their participation.
Immediate or delayed hypersensitivity to digoxin or trametinib
Immediate or delayed hypersensitivity to digoxin
Any serious known immediate or delayed hypersensitivity reaction(s) to GSK or idiosyncrasy to drugs chemically related to the investigational drug.
Have a known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to AEB or BYL
A known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to any of the study drugs or their excipients that, in the opinion of the investigator or medical monitor, contraindicates participation
Have a known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to vemurafenib or thyrotropin alpha (Thyrogen)
Have a known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to pazopanib or topotecan
Known hypersensitivity reaction or idiosyncrasy to erlotinib
Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to pazopanib or everolimus (such as sirolimus or temsirolimus)
EXPANSION COHORT ONLY: Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to pazopanib or everolimus (such as sirolimus or temsirolimus)
Have a known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to GSK or LSD inhibitors that contraindicates their participation.
Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to paclitaxel, including polyethoxylated castor oil, alcohol, or their excipients
Have a known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to crizotinib
Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to eltrombopag or its excipient, or azacitidine, that contraindicates the subjects' participation
Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to the study drug or their excipients.
Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to pazopanib or excipients that contraindicates participation.
Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to any of the study agents or their excipients that, in the opinion of the Investigator or GSK medical monitor , contra-indicates participation
Have a known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to dabrafenib, rosuvastatin, and midazolam, or excipients that contraindicate their participation; or have an allergy to cherries.
Have a known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to GSK or excipients that contraindicate their participation
Have a known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to study drugs (GSK, docetaxel, paclitaxel, carboplatin, pemetrexed, cisplatin) and or their excipients that contraindicate their participation.
Have a known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to GSKor enzalutamide or excipients.
Have a known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to study treatment or excipients that contraindicate their participation.
Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to pazopanib or excipients that contraindicates participation.
Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to pazopanib
Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to the study drugs or excipients.
A known immediate or delayed hypersensitivity reaction or idiosyncrasy that, in the opinion of the Medical Monitor is due to drugs chemically related to eltrombopag or excipients (e.g. mannitol)
Have a known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to eltrombopag or excipient that contraindicates the patients' participation
Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to GSK or any of the components of the study treatment.
Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to the study drugs
